pdufa.bio

PAPZIMEOS (zopapogene imadenovec-drba)

Updated ยทnext FDA decision on the calendar

PAPZIMEOS (zopapogene imadenovec-drba) The FDA approved it on May 27, 2026. 2 FDA decisions on record below. Every date links its source.

PGEN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 2 catalyst events for this program: 0 upcoming and 2 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

PDUFA · Aug 15, 2025 ✓ ApprovedPGENPDUFA · May 27, 2026 ✓ ApprovedPGEN

Questions

When is PAPZIMEOS (zopapogene imadenovec-drba)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for PAPZIMEOS (zopapogene imadenovec-drba); 2 FDA decisions are on record below.

What happened at PAPZIMEOS (zopapogene imadenovec-drba)'s most recent FDA decision?

On May 27, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has PAPZIMEOS (zopapogene imadenovec-drba) been approved by the FDA?

Yes. The FDA approved an application for PAPZIMEOS (zopapogene imadenovec-drba) on May 27, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.